Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.83
- Piotroski Score 3.00
- Grade Buy
- Symbol (NRIX)
- Company Nurix Therapeutics, Inc.
- Price $22.04
- Changes Percentage (-1.48%)
- Change -$0.33
- Day Low $21.75
- Day High $22.59
- Year High $29.56
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $33.00
- High Stock Price Target $41.00
- Low Stock Price Target $26.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.66
- Trailing P/E Ratio -5.89
- Forward P/E Ratio -5.89
- P/E Growth -5.89
- Net Income $-143,948,000
Income Statement
Quarterly
Annual
Latest News of NRIX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
A list of top small-cap healthcare stocks includes Nurix Therapeutics, Inc. (NASDAQ:NRIX), a company focused on novel therapies for cancer and inflammatory diseases. NRIX's strategic partnerships and ...
By Yahoo! Finance | 2 months ago -
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional investors who own 66%
Ownership research and analyst forecasts help investors understand stock opportunities. Nurix Therapeutics has institutions as top shareholders, indicating confidence in its future. Insider ownership ...
By Yahoo! Finance | 4 months ago -
Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)
On June 20, 2024, CFO Houte Van of Nurix Therapeutics Inc sold 20,000 shares at $20.01 each, now owning 48,333 shares. The company focuses on developing small molecule therapies for cancer and immune ...
By Yahoo! Finance | 5 months ago
